Faculty profile

Raymond Lai

Back to faculty

ProfessorLaboratory Medicine & Pathology DeptUniversity of Alberta

Raymond Lai

Professor

Laboratory Medicine & Pathology Dept

Faculty of Medicine & Dentistry

University of Alberta

Edmonton, Alberta, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
12 publications in the last five years, latest in 2026.
Senior (last) author on 6 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2010.
Supervisor on 2 trainee awards (2 CIHR), most recently in 2011.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

117

Publications

2,735

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Alberta profile.

Latest papers

IL1RAP Antibody-Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers.
Cancer discovery · 2026
FOXM1 and NFκB Form a Positive Feedback Loop to Promote Cell Growth and Drug Resistance in Mantle Cell Lymphoma.
Cells · 2026 · senior author
The liquid lectin array detects compositional glycocalyx differences using multivalent DNA-encoded lectins on phage.
Cell chemical biology · 2024

All 117 publications

Latest funding

Nanodelivery Systems for Modulation of Chemotherapy Response in Invasive and Metastatic Breast Cancer
CIHR · 2014 · Co-investigator
$100,000
Preclinical evaluation of polynucleotide kinase/phosphatase as a therapeutic target.
CIHR · 2011 · Co-investigator
$357,058
Ligand guided polymeric nano-carriers for tumor targeted drug and oncogene silencing therapy: A strategy for chemosensitization of resistant cancers
CIHR · 2011 · Co-investigator

All 6 grants and awards

117 publications.

IL1RAP Antibody-Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers.

Zhang HF, De Dreuzy E, Huang YZ, Shin S, Huang QF, Delaidelli A, Yang X, Adamiak V, Lytle A, Arzoo A, Lizardo MM, Lin Q, Sanadi S, Rouleau M, Liu LX, Xu LY, Li EM, Lai R, Primus C, Reda El Sayed S, Bourhis L, Genin D, Demontrond L, Bouquet L, Labarthe Démolis L, Barberot A, Lameynardie S, Delabrière A, Hua H, Yang J, Ishima R, Imle R, Banito A, Slack GW, Savage KJ, Maris JM, Bosse KR, Dimitrov DS, Steidl C, Li W, Sainson RCA, Sorensen PH

Cancer discovery20261 citationsOpen Access

DOI: 10.1158/2159-8290.cd-25-1036 PMID: 41973074

FOXM1 and NFκB Form a Positive Feedback Loop to Promote Cell Growth and Drug Resistance in Mantle Cell Lymphoma.

Zhang Y, Song Y, Almowaled M, Shang C, Hua L, Sandhu I, Peters A, Chu MP, Wang P, Lai R

Cells2026Senior author

DOI: 10.3390/cells15090776 PMID: 42121877

The liquid lectin array detects compositional glycocalyx differences using multivalent DNA-encoded lectins on phage.

Lima GM, Jame-Chenarboo Z, Sojitra M, Sarkar S, Carpenter EJ, Yang CY, Schmidt E, Lai J, Atrazhev A, Yazdan D, Peng C, Volker EA, Ho R, Monteiro G, Lai R, Mahal LK, Macauley MS, Derda R

Cell chemical biology202415 citationsOpen Access

DOI: 10.1016/j.chembiol.2024.09.010 PMID: 39454580

ULK2 Is a Key Pro-Autophagy Protein That Contributes to the High Chemoresistance and Disease Relapse in FLT3-Mutated Acute Myeloid Leukemia.

Lai J, Yang C, Shang C, Chen W, Chu MP, Brandwein J, Lai R, Wang P

International journal of molecular sciences2024

DOI: 10.3390/ijms25010646 PMID: 38203816

Estrogen/Progesterone Receptor Loss, CTNNB1 and KRAS Mutations Are Associated With Local Recurrence or Distant Metastasis in Low-Grade Endometrial Endometrioid Carcinoma.

Chibbar R, Foerstner S, Suresh J, Chibbar R, Piche A, Kundapur D, Kanthan R, Kundapur V, Lee CH, Agrawal A, Lai R

Applied immunohistochemistry & molecular morphology : AIMM20235 citationsSenior authorOpen Access

DOI: 10.1097/pai.0000000000001102 PMID: 36695555

An In Vitro Model for Acute Myeloid Leukemia Relapse Using the SORE6 Reporter.

Lai J, Shang C, Chen W, Izevbaye I, Chu MP, Sandhu I, Brandwein J, Lai R, Wang P

International journal of molecular sciences2023

DOI: 10.3390/ijms25010496 PMID: 38203669

Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma.

Shang C, Lai J, Haque M, Chen W, Wang P, Lai R

International journal of molecular sciences2023Senior author

DOI: 10.3390/ijms241814337 PMID: 37762644

Silibinin induces immunogenic cell death in cancer cells and enhances the induced immunogenicity by chemotherapy.

Jafari S, Heydarian S, Lai R, Mehdizadeh Aghdam E, Molavi O

BioImpacts : BI2023

DOI: 10.34172/bi.2022.23698 PMID: 36816998

Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders.

Stubbins RJ, Lam R, Zhu J, Ghosh S, Mabilangan C, Kuruvilla J, Goswami RS, Lai R, Preiksaitis JK, Jain MD, Peters AC

Clinical lymphoma, myeloma & leukemia20223 citations

DOI: 10.1016/j.clml.2022.05.006 PMID: 35717340

Flow Cytometric Detection of the Double-Positive (CD4+CD8+)/PD-1bright T-Cell Subset Is Useful in Diagnosing Nodular Lymphocyte-Predominant Hodgkin Lymphoma.

Chen ZW, Wizniak J, Shang C, Lai R

Archives of pathology & laboratory medicine2022Senior author

DOI: 10.5858/arpa.2020-0726-oa PMID: 34506624

Nanodelivery Systems for Modulation of Chemotherapy Response in Invasive and Metastatic Breast Cancer

Co-investigatorCIHR2014Operating Grant

Principal investigators: Lavasanifar, Afsaneh

Keywords: Cancer Chemotherapy; Drug Delivery; Drug Resistance; Nanotechnology; Sirna Delivery; Targeted Therapy

$100,000

Preclinical evaluation of polynucleotide kinase/phosphatase as a therapeutic target.

Co-investigatorCIHR2011Operating Grant

Principal investigators: Weinfeld, Michael

Keywords: Chemotherapy; Dna Repair; Radiotherapy; Synthetic Lethality; Targeted Therapy

$357,058

Ligand guided polymeric nano-carriers for tumor targeted drug and oncogene silencing therapy: A strategy for chemosensitization of resistant cancers

Co-investigatorCIHR2011Operating Grant - PA: Alberta Cancer Foundation - Research (bridge funding)

Principal investigators: Lavasanifar, Afsaneh

Keywords: Cancer Chemotherapy; Drug Delivery; Drug Resistance; Nanotechnology; Sirna Delivery; Targeted Therapy

The suppression of DNA mismatch repair by the oncoprotein NPM-ALK.

SupervisorCIHR2011Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Bone, Kathleen M

Keywords: Dna Mismatch Repair; Immunoblotting; Immunoprecipitation; Lymphoma; Oncogenic Tyrosine Kinase; Post-Translational Modification; Protein Function; Site-Directed Mutagenesis; Tissue Culture; Tumorigenesis

$105,000

Suppression of DNA mismatch repair by the oncoprotein NPM-ALK

Nominated PICIHR2010Operating Grant

Principal investigators: Lai, Raymond K

Keywords: Dna Mismatch Repair; Lymphomagenesis; Microsatellite Instability; Npm-Alk; Tyrosine Kinase

$515,419

Biological significance of SALL4, a novel homeobox gene that is aberrantly expressed in ALK-expressing anaplastic large cell lymphoma

SupervisorCIHR2009CIHR Fellowship

Principal investigators: Molavi, Ommoleila

Keywords: Apoptosis Assay; Clonogenic Assay; Immunohistochemistry; Npm-Alk; Oncogenic Tyrosine Kinase; Sall4; Sirna; Stat3

$135,000

From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Raymond Lai

Research

Latest papers

Latest funding

IL1RAP Antibody-Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers.

FOXM1 and NF&#x3ba;B Form a Positive Feedback Loop to Promote Cell Growth and Drug Resistance in Mantle Cell Lymphoma.

The liquid lectin array detects compositional glycocalyx differences using multivalent DNA-encoded lectins on phage.

ULK2 Is a Key Pro-Autophagy Protein That Contributes to the High Chemoresistance and Disease Relapse in FLT3-Mutated Acute Myeloid Leukemia.

Estrogen/Progesterone Receptor Loss, CTNNB1 and KRAS Mutations Are Associated With Local Recurrence or Distant Metastasis in Low-Grade Endometrial Endometrioid Carcinoma.

An In Vitro Model for Acute Myeloid Leukemia Relapse Using the SORE6 Reporter.

Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma.

Silibinin induces immunogenic cell death in cancer cells and enhances the induced immunogenicity by chemotherapy.

Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders.

Flow Cytometric Detection of the Double-Positive (CD4+CD8+)/PD-1bright T-Cell Subset Is Useful in Diagnosing Nodular Lymphocyte-Predominant Hodgkin Lymphoma.

Nanodelivery Systems for Modulation of Chemotherapy Response in Invasive and Metastatic Breast Cancer

Preclinical evaluation of polynucleotide kinase/phosphatase as a therapeutic target.

Ligand guided polymeric nano-carriers for tumor targeted drug and oncogene silencing therapy: A strategy for chemosensitization of resistant cancers

The suppression of DNA mismatch repair by the oncoprotein NPM-ALK.

Suppression of DNA mismatch repair by the oncoprotein NPM-ALK

Biological significance of SALL4, a novel homeobox gene that is aberrantly expressed in ALK-expressing anaplastic large cell lymphoma

Frequent collaborators

Afsaneh Lavasanifar

Robert Ingham

Sunita Ghosh

Keshav Gopal

Todd McMullen

Liang Li

Tony Reiman

John Mackey

Sambasivarao Damaraju

Poul Sorensen

Hasan Uludag

Christopher Venner

John Seubert

Azita Haddadi

Joseph Brandwein

Karen Doucette

Matthew Li

Joan Robinson

Raimar Loebenberg

Anita Agrawal

Ming Tsao

Rani Kanthan

James Young

Ratmir Derda

Edan Foley

Lynne-Marie Postovit

Daniel Roth

Brian Chiu

Paul Jurasz

Christian Steidl

FOXM1 and NFκB Form a Positive Feedback Loop to Promote Cell Growth and Drug Resistance in Mantle Cell Lymphoma.